Skip to main content

Advertisement

SpringerLink
Log in

Sexual function in patients with benign prostatic hyperplasia

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Sexual health has significant impact on quality of life among men with benign prostatic hyperplasia (BPH). The degree of sexual dysfunction matches the severity of lower urinary tract symptoms (LUTS). Treatment of BPH affects not only LUTS, but sexual function as well. Medical, surgical, and minimally invasive therapies differ in their effect on erectile function, ejaculation, and sexual satisfaction. Choice of treatment modality takes into account baseline sexual function and patient expectations. This review outlines the relationship between LUTS and sexual function and how they change with the currently available treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Abrams P: New words for old: lower urinary tract symptoms for ‘prostatism’. BMJ 1994, 308:929–930.

    PubMed  CAS  Google Scholar 

  2. Ohnishi K, Watanabe H, Ohe H: Development of benign prostatic hyperplasia estimated from ultrasonic measurement with long-term follow-up. J Exp Med 1987, 151:51–56.

    CAS  Google Scholar 

  3. Girman C, Jacobsen S, Guess H, et al.: Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995, 153:1510–1515.

    Article  PubMed  CAS  Google Scholar 

  4. Birkhoff J: Natural history of benign prostatic hyperplasia. In Benign Prostatic Hypertrophy. Edited by Hinman F. New York: Springer-Verlag; 1983.

    Google Scholar 

  5. Fosså SD: Quality of life in advanced prostate cancer. Semin Oncol 1996, 23:6(suppl):32–34.

    Google Scholar 

  6. Streiner DL, Norman GR: Health Measurement Scales: A Practical Guide to Their Development and Use. Oxford: Oxford University Press; 1987.

    Google Scholar 

  7. McDowell I, Newell C: Measuring Health: A Guide to Rating Scales and Questionnaires. New York: Oxford University Press; 1989.

    Google Scholar 

  8. Brazier JE, Harper R, Jones NMB, et al.: Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992, 305:160–164.

    PubMed  CAS  Google Scholar 

  9. Millan IH, Rodriguez JV, Romero JL, et al.: Sexual activity and surgery for benign prostatic hyperplasia. Arch Esp Urol 2001, 54:53–60. One of the few recent studies reporting on the impact of surgery in BPH.

    Google Scholar 

  10. Stewart AL, Hays RD, Ware JE: The MOS short form general health survey: reliability and validity in a patient population. Med Care 1988, 26:724–735.

    Article  PubMed  CAS  Google Scholar 

  11. Bergner M, Bobbitt RA, Carter WB, Gilson BS: The sickness impact profile: development and final revision of a health status measure. Med Care 1981, 19:787–805.

    Article  PubMed  CAS  Google Scholar 

  12. McNair DM, Lorr M, Droppleman LF: Manual: Profile of Mood States. San Diego: Educational and Industrial Testing Service; 1971.

    Google Scholar 

  13. Rosen RC, Riley A, Wagner G, et al.: The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997, 49:822–830. Describes the basis for this extremely important clinical and research instrument.

    Article  PubMed  CAS  Google Scholar 

  14. O’Leary MP, Fowler FJ, Lenderking WR, et al.: A brief male sexual function inventory for urology. Urology 1995, 46:697–706.

    Article  PubMed  CAS  Google Scholar 

  15. Helgason AR, Adolfsson J, Dickman P, et al.: Factors associated with waning sexual function among elderly men and prostate cancer patients. J Urol 1997, 158:155–159.

    Article  PubMed  CAS  Google Scholar 

  16. Feldman HA, Goldstein I, Hatzichristou DG, et al.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151:54–61. This is a landmark study providing an invaluable population reference.

    PubMed  CAS  Google Scholar 

  17. Hermann M, Untergasser G, Rumpold H, Berger P: Aging of the male reproductive system. Exp Gerontol 2000, 35:1267–1279.

    Article  PubMed  CAS  Google Scholar 

  18. Baniel J, Israilov S, Shmueli J, et al.: Sexual function in 131 patients with benign prostatic hyperplasia before prostatectomy. Eur Urol 2000, 38:53–58.

    Article  PubMed  CAS  Google Scholar 

  19. Kirby RS, Fitzpatrick JM, Kirby MG, Fitzpatrick A: Shared care for benign prostatic hyperplasia. In Textbook of Benign Prostatic Hyperplasia. Edited by Kirby RS.: Oxford: Isis Medical Media; 1997.

    Google Scholar 

  20. Furuya S, Kumamoto Y, Yokoyama E: Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982, 128:836–839.

    PubMed  CAS  Google Scholar 

  21. Caine M, Pfau A, Perlberg S: The use of alpha-adrenergic blockers in benign prostatic hyperplasia. BJU Int 1976, 48:255–263.

    CAS  Google Scholar 

  22. Hofner K, Claes H, De Reijke TM, et al.: Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999, 36:335–341.

    Article  PubMed  CAS  Google Scholar 

  23. Kohn FM, Schill WB: The alpha-sympathomimetic midodrine as a tool for diagnosis and treatment of sperm transport disturbances. Andrologia 1994, 26:283–287.

    Article  PubMed  CAS  Google Scholar 

  24. Kirby RS, Andersen M, Gratzke P, et al.: A combined analysis of double-blind trials of the efficacy of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia, BJU Int 2001, 87:192–200.

    Article  PubMed  CAS  Google Scholar 

  25. Wilson J: The pathogenesis of benign prostatic hyperplasia. Am J Med 1980, 68:745–756.

    Article  PubMed  CAS  Google Scholar 

  26. Silver R, Wiley E, Thigpen A: Cell type specific expression of steroid 5a reductase 2. J Urol 1994, 152:438–442.

    PubMed  CAS  Google Scholar 

  27. McConnell J, Wilson J, George F: Finasteride, an inhibitor of 5a reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992, 74:505–508.

    Article  PubMed  CAS  Google Scholar 

  28. Gormley G, Stoner E, Bruskewitz R: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992, 327:1185–1191.

    Article  PubMed  CAS  Google Scholar 

  29. The Finasteride Study Group: Finasteride in the treatment of benign prostatic hyperplasia. Prostate 1993, 22:291–299.

    Article  Google Scholar 

  30. Chueh SC, Yu HJ, Chiu TY, et al.: Treating benign prostatic hyperplasia with finasteride in Chinese men: one-year experience. J Formos Med Assoc 1996, 95:650–652.

    PubMed  CAS  Google Scholar 

  31. Peters DH, Sorkin EM: Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993, 46:177–208.

    PubMed  CAS  Google Scholar 

  32. Uygur MC, Gur E, Arik AI, et al.: Erectile dysfunction following treatments of benign prostatic hyperplasia: a prospective study. Andrologia 1998, 30:5–10.

    Article  PubMed  CAS  Google Scholar 

  33. Bruskewitz R, Girman CJ, Fowler J, et al.: Effect of finasteride on bother and other health-related quality of life aspects with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999, 54:670–678.

    Article  PubMed  CAS  Google Scholar 

  34. Fitzpatrick JM, Lynch TH: Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia. Urol Clin North Am 1995, 22:407–412.

    PubMed  CAS  Google Scholar 

  35. Habib F, Ross M, Buck A: In vitro evaluation of pollen extract, cernitin T-60, in the regulation of prostate cell growth. BJU Int 1990, 66:393–397.

    CAS  Google Scholar 

  36. Carraro JC, Raynaud JP, Koch G, et al.: Comparison of phytotherapy (Permixon) with finasteride in treatment of benign prostatic hyperplasia: a randomised international study of 1,098 patients. Prostate 1996, 29:231–240.

    Article  PubMed  Google Scholar 

  37. Fitzpatrick JM: A critical evaluation of technological innovations in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 1998, 81(suppl):56–63.

    Article  Google Scholar 

  38. Thomas K, Cornaby A, Hammadeh M, et al.: Transurethral vaporization of the prostate: a promising new technique. BJU Int 1997, 79:186–189.

    Article  CAS  Google Scholar 

  39. Hahn R, Sandfeldt L, Nyman C: Double-blind randomized study of symptoms associated with absorption of glycine 1.5% or mannitol 3% during transurethral resection of the prostate. J Urol 1998, 160:397–401.

    Article  PubMed  CAS  Google Scholar 

  40. Dorflinger T, Jensen FS, Krarup T, Walter S: Transurethral prostatectomy compared with incision of the prostate in the treatment of prostatism caused by small benign prostatic glands. Scand J Urol Nephrol 1992, 26:333–338.

    Article  PubMed  CAS  Google Scholar 

  41. Kunelius P, Hakkinen J, Lukkarinen O: Sexual function in patients with benign prostatic hyperplasia before and after transurethral resection of the prostate. Urol Res 1998, 26:7–9.

    Article  PubMed  CAS  Google Scholar 

  42. Libman E, Fichten C: Prostatectomy and sexual function. Urology 1987, 29:467–478.

    Article  PubMed  CAS  Google Scholar 

  43. Kinn AC, Helmey-Dhejne C, Larsson J: Sexual function one year after transurethral prostatic resection. Patient’s own assessment. Scan J Urol Nephrol 1998, 32:33–35.

    Article  CAS  Google Scholar 

  44. So EP, Ho PC, Bodenstab W, Parsons CL: Erectile impotence associated with transurethral prostatectomy. Urology 1982, 19:259–262.

    Article  PubMed  CAS  Google Scholar 

  45. Orandi A: Transurethral incision of the prostate compared with transurethral resection of the prostate in 132 matching cases. J Urol 1987, 138:810–815.

    PubMed  CAS  Google Scholar 

  46. Orandi A: Incision of the prostate (TUIP): 646 cases in 15 years—a chronological appraisal. BJU Int 1985, 57:703–707.

    CAS  Google Scholar 

  47. Edwards L, Powell C: An objective comparison of transurethral resection and bladder neck incision in the treatment of prostatic hypertrophy. J Urol 1982, 128:325–327.

    PubMed  CAS  Google Scholar 

  48. Ronzoni G, De Vecchis M: Preservation of anterograde ejaculation after transurethral ejaculation of both prostate and bladder neck. BJU Int 1998, 81: 830–833.

    Article  CAS  Google Scholar 

  49. Sirls LT, Ganabathi K, Zimmern PE, et al.: Transurethral incision of the prostate: an objective and subjective evaluation of long-term efficacy. J Urol 1993, 150:1615–1621.

    PubMed  CAS  Google Scholar 

  50. Cornford C, Biyani C, Powell C: Transurethral incision of the prostate using the holmium:YAG laser: a catheterless procedure. J Urol 1998, 159:1229–1231.

    Article  PubMed  CAS  Google Scholar 

  51. Roos N, Wennberg J, Malenka D, et al.: Mortality and reoperation after transurethral resection of the prostate for benign prostatic hyperplasia. N Eng J Med 1989, 320:1120–1124.

    Article  CAS  Google Scholar 

  52. Lieb Z, Rothem A, Lev A, Servadio C: Histopathological observations in the canine prostate treated by local hyperthermia. Prostate 1986, 8:93–102.

    Article  Google Scholar 

  53. Arai Y, Aoki Y, Okubo K, et al.: Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J Urol 2000, 164:1206–1211.

    Article  PubMed  CAS  Google Scholar 

  54. Mulligan ED, Lynch TH, Mulvin D, et al.: High-intensity focused ultrasound in the treatment of benign prostatic hyperplasia. BJU Int 1997, 79:177–180.

    Article  CAS  Google Scholar 

  55. Sullivan LD, McLoughlin MG, Goldenberg LG, et al.: Early experience with high-intensity focused ultrasound for the treatment of benign prostatic hypertrophy. BJU Int 1997, 79:172–176.

    Article  CAS  Google Scholar 

  56. Ramon J, Lynch TH, Eardley I, et al.: Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study. BJU Int 1997, 80:128–135.

    Article  CAS  Google Scholar 

  57. Schulman C, Zlotta A: Transurethral needle ablation (TUNA) of the prostate: clinical experience with two years’ follow-up in patients with benign prostatic hyperplasia. Eur Urol 1996, 30:985–990.

    Google Scholar 

  58. Bruskewitz R, Issa MM, Roehrborn CG, et al.: A prospective, randomised 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998, 159:1588–1593.

    Article  PubMed  CAS  Google Scholar 

  59. Lepor H: Editorial comment. J Urol 1998, 159:1588–1594.

    Article  Google Scholar 

  60. McLoughlin J, Keane P, Jager R, et al.: Dilation of the prostatic urethra with a 35 mm balloon. BJU Int 1991, 67:177–181.

    Article  CAS  Google Scholar 

  61. Reddy PK: Role of balloon dilation in the treatment of benign prostatic hyperplasia. Prostate 1990, 3(suppl):39–48.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University College Dublin, Mater Misericordiae Hospital, 47 Eccles Street, Dublin 7, Ireland

    Paul K. Hegarty MD, Nicholas J. Hegarty MD & John M. Fitzpatrick MD

Authors
  1. Paul K. Hegarty MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas J. Hegarty MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John M. Fitzpatrick MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hegarty, P.K., Hegarty, N.J. & Fitzpatrick, J.M. Sexual function in patients with benign prostatic hyperplasia. Curr Urol Rep 2, 292–296 (2001). https://doi.org/10.1007/s11934-001-0066-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-001-0066-0

Keywords

Search

Navigation